Cited by 236Attention Deficit Hyperactivity DisorderNeurotransmitter Receptor Influence on BehaviorSchizophrenia research and treatment

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Clinically Relevant Doses of Methylphenidate Significantly Occupy Norepinephrine Transporters in Humans In Vivo

Open access

Hannestad, Jonas, Gallezot, Jean-Dominique, Planeta-Wilson, Beata, Lin, Shu-Fei, Williams, Wendol A., van Dyck, Christopher H., Malison, Robert T., Carson, Richard E., Ding, Yu-Shin·2010·Biological Psychiatry

DOI 10.1016/j.biopsych.2010.06.017PMC PMC3742016

Open this paper in CoChat — free account

Abstract

Background Attention-deficit/hyperactivity disorder is a psychiatric disorder that starts in childhood. The mechanism of action of methylphenidate, the most common treatment for attention deficit hyperactivity disorder, is unclear. In vitro, the affinity of methylphenidate for the norepinephrine transporter (NET) is higher than that for the dopamine transporter (DAT). The goal of this study was to use positron emission tomography to measure the occupancy of brain norepinephrine transporter by methylphenidate in vivo in humans. Methods We used (S,S)-[¹¹C] methylreboxetine ([¹¹C]MRB) to determine the effective dose 50 (ED₅₀) of methylphenidate for NET. In a within-subject design, healthy subjects (n = 11) received oral, single-blind placebo and 2.5, 10, and 40 mg of methylphenidate 75 min before [¹¹C]MRB injection. Dynamic positron emission tomography imaging was performed for 2 hours with the High Resolution Research Tomograph. The multilinear reference tissue model with occipital cortex as the reference region was used to estimate binding potential non-displaceable (BP(ND)) in the thalamus and other NET-rich regions. Results BP(ND) was reduced by methylphenidate in a dose-dependent manner in thalamus and other NET-rich regions. The global ED₅₀ was estimated to be .14 mg/kg; therefore, the average clinical maintenance dose of methylphenidate (.35-.55 mg/kg) produces 70% to 80% occupancy of NET. Conclusions For the first time in humans, we demonstrate that oral methylphenidate significantly occupies NET at clinically relevant doses. The ED₅₀ is lower than that for DAT (.25 mg/kg), suggesting the potential relevance of NET inhibition in the therapeutic effects of methylphenidate in attention-deficit/hyperactivity disorder.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.biopsych.2010.06.017

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single subject brain
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Self-citation
Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter
Pacholczyk, T., Blakely, R. D., & Amara, S. G. (1991) · Nature · doi:10.1038/350350a0 · Cited by 933
Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate
Volkow, N. D., Wang, G.-J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y.-S., Hitzemann, R., & Pappas, N. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1325 · Cited by 885
Self-citation
The neural correlates of attention deficit hyperactivity disorder: an ALE meta‐analysis
Dickstein, S. G., Bannon, K., Xavier Castellanos, F., & Milham, M. P. (2006) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2006.01671.x · Cited by 745
Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines
Morón, J. A., Brockington, A., Wise, R. A., Rocha, B. A., & Hope, B. T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-02-00389.2002 · Cited by 681
Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration
Solanto, M. V. (1998) · Behavioural Brain Research · doi:10.1016/s0166-4328(97)00175-7 · Cited by 677
Linearized Reference Tissue Parametric Imaging Methods: Application to [ 11 C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human Brain
Ichise, M., Liow, J., Lu, J., Takano, A., Modell, K. J., Toyama, H., Suhara, T., Suzuki, K., Innis, R. B., & Carson, R. E. (2003) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000085441.37552.ca · Cited by 651
Self-citation
Methylphenidate Preferentially Increases Catecholamine Neurotransmission within the Prefrontal Cortex at Low Doses that Enhance Cognitive Function
Berridge, C. W., Devilbiss, D. M., Andrzejewski, M. E., Arnsten, A. F. T., Kelley, A. E., Schmeichel, B., Hamilton, C., & Spencer, R. C. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.022 · Cited by 617

Show all 41 references

Sorted by citations

The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder
del Campo, N., Chamberlain, S. R., Sahakian, B. J., & Robbins, T. W. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.02.036 · Cited by 685
The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities
Faraone, S. V. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.001 · Cited by 631
A Review of Heterogeneity in Attention Deficit/Hyperactivity Disorder (ADHD)
Luo, Y., Weibman, D., Halperin, J. M., & Li, X. (2019) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2019.00042 · Cited by 394
Cognitive Effects of Cancer and Cancer Treatments
Ahles, T. A., & Root, J. C. (2018) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050817-084903 · Cited by 416
Effects of stimulants on brain function in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis
Rubia, K., Alegria, A. A., Cubillo, A. I., Smith, A. B., Brammer, M. J., & Radua, J. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.10.016 · Cited by 315
“The increase of IFG/insula activation with methylphenidate is likely mediated by both noradrenergic and dopaminergic mechanisms, given that in frontal regions both in humans (15,69,70) and in animals (69,70) methylphenidate increases noradrenaline equally or more than dopamine via reuptake inhibition of noradrenaline…”
Psychostimulants and Cognition: A Continuum of Behavioral and Cognitive Activation
Wood, S., Sage, J. R., Shuman, T., & Anagnostaras, S. G. (2014) · Pharmacological Reviews · doi:10.1124/pr.112.007054 · Cited by 259
Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis
Fusar-Poli, P., Rubia, K., Rossi, G., Sartori, G., & Balottin, U. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11060940 · Cited by 260
Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder
Volkow, N. D., Wang, G.-J., Tomasi, D., Kollins, S. H., Wigal, T. L., Newcorn, J. H., Telang, F. W., Fowler, J. S., Logan, J., Wong, C. T., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4461-11.2012 · Cited by 237
Methylphenidate Normalizes Fronto-Striatal Underactivation During Interference Inhibition in Medication-Naïve Boys with Attention-Deficit Hyperactivity Disorder
Rubia, K., Halari, R., Cubillo, A., Smith, A. B., Mohammad, A.-M., Brammer, M., & Taylor, E. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.30 · Cited by 184
Methylphenidate Normalizes Frontocingulate Underactivation During Error Processing in Attention-Deficit/Hyperactivity Disorder
Rubia, K., Halari, R., Mohammad, A.-M., Taylor, E., & Brammer, M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.018 · Cited by 171
Cognitive effects of methylphenidate in healthy volunteers: a review of single dose studies
Linssen, A. M. W., Sambeth, A., Vuurman, E. F. P. M., & Riedel, W. J. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001594 · Cited by 159
A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor
Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., & Wefel, J. S. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0723-1 · Cited by 161
RETRACTED: Association of Posttraumatic Stress Disorder With Reduced In Vivo Norepinephrine Transporter Availability in the Locus Coeruleus
Pietrzak, R. H., Gallezot, J., Ding, Y., Henry, S. E., Potenza, M. N., Southwick, S. M., Krystal, J. H., Carson, R. E., & Neumeister, A. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.399 · Cited by 127
Self-citation
Retracted
Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects
Dolder, P. C., Müller, F., Schmid, Y., Borgwardt, S. J., & Liechti, M. E. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4650-5 · Cited by 117
Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys
Cubillo, A., Smith, A. B., Barrett, N., Giampietro, V., Brammer, M. J., Simmons, A., & Rubia, K. (2014) · Cerebral Cortex · doi:10.1093/cercor/bhs296 · Cited by 116
Central noradrenaline transporter availability in highly obese, non-depressed individuals
Hesse, S., Becker, G., Rullmann, M., Bresch, A., Luthardt, J., Hankir, M. K., Zientek, F., Reißig, G., Patt, M., Arélin, K., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3590-3 · Cited by 106
Self-citation
Effects of Methylphenidate on Resting-State Functional Connectivity of the Mesocorticolimbic Dopamine Pathways in Cocaine Addiction
Konova, A. B., Moeller, S. J., Tomasi, D. G., Volkow, N. D., & Goldstein, R. Z. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1129 · Cited by 104
Cognitive enhancers for the treatment of ADHD
Bidwell, L. C., McClernon, F. J., & Kollins, S. H. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.05.002 · Cited by 104
Amygdala and Hypothalamus: Historical Overview With Focus on Aggression
Gouveia, F. V., Hamani, C., Fonoff, E. T., Brentani, H., Alho, E. J. L., Morais, R. M. C. B., de Souza, A. L., Rigonatti, S. P., & Martinez, R. C. R. (2019) · Neurosurgery · doi:10.1093/neuros/nyy635 · Cited by 103
Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD
Ding, Y., Naganawa, M., Gallezot, J., Nabulsi, N., Lin, S.-F., Ropchan, J. R., Weinzimmer, D. P., McCarthy, T. J., Carson, R. E., Huang, Y. H., et al. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.08.001 · Cited by 96
Self-citation
Drug-specific laterality effects on frontal lobe activation of atomoxetine and methylphenidate in attention deficit hyperactivity disorder boys during working memory
Cubillo, A., Smith, A. B., Barrett, N., Giampietro, V., Brammer, M., Simmons, A., & Rubia, K. (2014) · Psychological Medicine · doi:10.1017/s0033291713000676 · Cited by 88
Atomoxetine modulates spontaneous and sensory-evoked discharge of Locus coeruleus noradrenergic neurons
Bari, A., & Aston-Jones, G. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.020 · Cited by 85
Methylphenidate produces selective enhancement of declarative memory consolidation in healthy volunteers
Linssen, A. M. W., Vuurman, E. F. P. M., Sambeth, A., & Riedel, W. J. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2605-9 · Cited by 88
Methylphenidate Enhances Executive Function and Optimizes Prefrontal Function in Both Health and Cocaine Addiction
Moeller, S. J., Honorio, J., Tomasi, D. G., Parvaz, M. A., Woicik, P. A., Volkow, N. D., & Goldstein, R. Z. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhs345 · Cited by 79
Methylphenidate Exerts Dose-Dependent Effects on Glutamate Receptors and Behaviors
Cheng, J., Zhe, X., Duffney, L. J., Wei, J., Liu, A., Liu, S., Chen, G., & Yan, Z. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.04.003 · Cited by 77
Dissociable effects of methylphenidate, atomoxetine and placebo on regional cerebral blood flow in healthy volunteers at rest: A multi-class pattern recognition approach
Marquand, A. F., O’Daly, O., Simoni, S. D., Alsop, D. C., Maguire, R. P., Williams, S., Zelaya, F. O., & Mehta, M. A. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.01.058 · Cited by 70
Review of recent studies on interventions for cognitive deficits in patients with cancer
Gehring, K., Roukema, J. A., & Sitskoorn, M. M. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.202 · Cited by 72
Dopaminergic involvement during mental fatigue in health and cocaine addiction
Moeller, S. J., Tomasi, D. G., Honorio, J., Volkow, N. D., & Goldstein, R. Z. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.110 · Cited by 77
Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents
Kowalczyk, O. S., Cubillo, A. I., Smith, A., Barrett, N., Giampietro, V., Brammer, M., Simmons, A., & Rubia, K. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.07.139 · Cited by 63
Current Pharmacological Treatments for ADHD
Groom, M. J., & Cortese, S. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_330 · Cited by 74
Decreased norepinephrine transporter availability in obesity: Positron Emission Tomography imaging with (S,S)-[11C]O-methylreboxetine
Li, C.-S. R., Potenza, M. N., Lee, D. E., Planeta, B. M., Gallezot, J., Labaree, D. C., Henry, S. E., Nabulsi, N., Sinha, R., Ding, Y., et al. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.10.004 · Cited by 68
Self-citation
Neuroanatomic and cognitive abnormalities in attention-deficit/hyperactivity disorder in the era of ‘high definition’ neuroimaging
Baroni, A., & Castellanos, F. X. (2014) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.08.005 · Cited by 68
LPHN3 and attention‐deficit/hyperactivity disorder: a susceptibility and pharmacogenetic study
Bruxel, E. M., Salatino-Oliveira, A., Akutagava-Martins, G. C., Tovo-Rodrigues, L., Genro, J., Zeni, C., Polanczyk, G. V., Chazan, R., Schmitz, M., Arcos-Burgos, M., et al. (2015) · Genes, Brain and Behavior · doi:10.1111/gbb.12224 · Cited by 77
Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults
Koblan, K., Hopkins, S., Sarma, K., Jin, F., Goldman, R., Kollins, S., & Loebel, A. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.124 · Cited by 60
The Norepinephrine Transporter in Attention-Deficit/Hyperactivity Disorder Investigated With Positron Emission Tomography
Vanicek, T., Spies, M., Rami-Mark, C., Savli, M., Höflich, A., Kranz, G. S., Hahn, A., Kutzelnigg, A., Traub-Weidinger, T., Mitterhauser, M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1226 · Cited by 61
Emotion Processing Dysfunction in Alzheimer’s Disease: An Overview of Behavioral Findings, Systems Neural Correlates, and Underlying Neural Biology
Chaudhary, S., Zhornitsky, S., Chao, H. H., van Dyck, C. H., & Li, C. R. (2022) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/15333175221082834 · Cited by 66
Evaluation of [11C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates
Gallezot, J., Weinzimmer, D. P., Nabulsi, N., Lin, S.-F., Fowles, K., Sandiego, C. M., McCarthy, T. J., Maguire, R. P., Carson, R. E., & Ding, Y. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.09.040 · Cited by 59
Self-citation
A narrative review of risk factors and interventions for cancer- related cognitive impairment
Bai, L., & Yu, E. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-6443 · Cited by 64
Methylphenidate Effects on Prefrontal Functioning During Attentional-Capture and Response Inhibition
Pauls, A. M., O'Daly, O. G., Rubia, K., Riedel, W. J., Williams, S. C. R., & Mehta, M. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.028 · Cited by 57
Areas of the Brain Modulated by Single-Dose Methylphenidate Treatment in Youth with ADHD During Task-Based fMRI
Czerniak, S., Şıkoğlu, E. M., King, J. A., Kennedy, D. N., Mick, E. O., Frazier, J. A., & Moore, C. M. (2013) · Harvard Review of Psychiatry · doi:10.1097/hrp.0b013e318293749e · Cited by 57
Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe
Huß, M., Chen, W., & Ludolph, A. G. (2015) · Clinical Drug Investigation · doi:10.1007/s40261-015-0336-0 · Cited by 60
Systemic inflammation enhances stimulant-induced striatal dopamine elevation
Petrulli, J. R., Kalish, B., Nabulsi, N., Huang, Y. H., Hannestad, J. O., & Morris, E. D. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.18 · Cited by 57
Self-citation
Noradrenergic Deficits in Parkinson Disease Imaged with11C-MeNER
Nahimi, A., Sommerauer, M., Kinnerup, M. B., Østergaard, K., Winterdahl, M., Jacobsen, J., Schacht, A. C., Johnsen, B., Damholdt, M. F., Borghammer, P., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.190975 · Cited by 56
Dopamine and norepinephrine receptors participate in methylphenidate enhancement of in vivo hippocampal synaptic plasticity
Jenson, D., Yang, K., Acevedo-Rodriguez, A., Levine, A., Broussard, J. I., Tang, J., & Dani, J. A. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.029 · Cited by 52
ADHD pharmacogenetics across the life cycle: New findings and perspectives
Bruxel, E. M., Akutagava-Martins, G. C., Salatino-Oliveira, A., Contini, V., Kieling, C., Hutz, M., & Rohde, L. (2014) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32240 · Cited by 44
Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial
Rezaei, F., Emami, M., Zahed, S., Morabbi, M.-J., Farahzadi, M., & Akhondzadeh, S. (2015) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/s40199-015-0092-y · Cited by 43
Distributed effects of methylphenidate on the network structure of the resting brain: A connectomic pattern classification analysis
Sripada, C., Kessler, D. A., Welsh, R. C., Angstadt, M., Liberzon, I., Phan, K. L., & Scott, C. D. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.05.016 · Cited by 52
Differential involvement of brainstem noradrenergic and midbrain dopaminergic nuclei in cognitive control
Köhler, S., Bär, K., & Wagner, G. (2016) · Human Brain Mapping · doi:10.1002/hbm.23173 · Cited by 57
Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study
Zheng, G., Xue, W., Wang, P., Yang, F., Li, B., Li, X., Li, Y., Yao, X., & Zhu, F. (2016) · Scientific Reports · doi:10.1038/srep26883 · Cited by 51
Effects of norepinephrine transporter gene variants on NET binding in ADHD and healthy controls investigated by PET
Sigurdardottir, H. L., Kranz, G. S., Rami‐Mark, C., James, G. M., Vanicek, T., Gryglewski, G., Kautzky, A., Hienert, M., Traub‐Weidinger, T., Mitterhauser, M., et al. (2016) · Human Brain Mapping · doi:10.1002/hbm.23071 · Cited by 51
Modulation of Social Influence by Methylphenidate
Campbell-Meiklejohn, D. K., Simonsen, A., Jensen, M., Wohlert, V., Gjerløff, T., Scheel‐Krüger, J., Møller, A., Frith, C., & Roepstorff, A. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.337 · Cited by 54
Pills or Push-Ups? Effectiveness and Public Perception of Pharmacological and Non-Pharmacological Cognitive Enhancement
Caviola, L., & Faber, N. S. (2015) · Frontiers in Psychology · doi:10.3389/fpsyg.2015.01852 · Cited by 48
Noradrenergic Activity in the Human Brain: A Mechanism Supporting the Defense Against Hypoglycemia
Belfort‐DeAguiar, R., Gallezot, J., Hwang, J. J., Elshafie, A., Yeckel, C. W., Chan, O. T. M., Carson, R. E., Ding, Y., & Sherwin, R. S. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02717 · Cited by 49
Self-citation
Effects of non-pharmacological or pharmacological interventions on cognition and brain plasticity of aging individuals
Pieramico, V., Esposito, R., Cesinaro, S., Frazzini, V., & Sensi, S. L. (2014) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2014.00153 · Cited by 52
Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder
Shang, C., Yan, C., Lin, H., Tseng, W. I., Castellanos, F. X., & Gau, S. S. (2016) · Psychological Medicine · doi:10.1017/s0033291716001938 · Cited by 48
Neuroimaging-Aided Prediction of the Effect of Methylphenidate in Children with Attention-Deficit Hyperactivity Disorder: A Randomized Controlled Trial
Ishii‐Takahashi, A., Takizawa, R., Nishimura, Y., Kawakubo, Y., Hamada, K., Okuhata, S., Kawasaki, S., Kuwabara, H., Shimada, T., Todokoro, A., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.128 · Cited by 48
Neurofunctional Effects of Methylphenidate and Atomoxetine in Boys with Attention-Deficit/Hyperactivity Disorder During Time Discrimination
Smith, A., Cubillo, A., Barrett, N., Giampietro, V., Simmons, A., Brammer, M., & Rubia, K. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.030 · Cited by 53
Unravelling the effects of methylphenidate on the dopaminergic and noradrenergic functional circuits
Dipasquale, O., Martins, D., Sethi, A., Veronese, M., Hesse, S., Rullmann, M., Sabri, O., Turkheimer, F., Harrison, N. A., Mehta, M. A., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0724-x · Cited by 46
Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate
van Dyck, C. H., Arnsten, A. F. T., Padala, P. R., Brawman‐Mintzer, O., Lerner, A. J., Porsteinsson, A. P., Scherer, R. W., Levey, A. I., Herrmann, N., Jamil, N., et al. (2020) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2020.04.026 · Cited by 53
Adult attention-deficit/hyperactivity disorder is associated with reduced norepinephrine transporter availability in right attention networks: a (S,S)-O-[11C]methylreboxetine positron emission tomography study
Ulke, C., Rullmann, M., Huang, J., Luthardt, J., Becker, G.-A., Patt, M., Meyer, P. M., Tiepolt, S., Hesse, S., Sabri, O., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0619-y · Cited by 43
The neuroprotective effect of lithium against high dose methylphenidate: Possible role of BDNF
Motaghinejad, M., Seyedjavadein, Z., Motevalian, M., & Asadi, M. (2016) · NeuroToxicology · doi:10.1016/j.neuro.2016.06.010 · Cited by 43
The Effects of Methylphenidate on Resting-State Functional Connectivity of the Basal Nucleus of Meynert, Locus Coeruleus, and Ventral Tegmental Area in Healthy Adults
Kline, R. L., Zhang, S., Farr, O. M., Hu, S., Záborszky, L., Samanez-Larkin, G. R., & Li, C. R. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00149 · Cited by 43
Atomoxetine increases fronto-parietal functional MRI activation in attention-deficit/hyperactivity disorder: A pilot study
Bush, G., Holmes, J., Shin, L. M., Surman, C. B. H., Makris, N., Mick, E. O., Seidman, L. J., & Biederman, J. (2012) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2012.09.004 · Cited by 41
Methylphenidate and desipramine combined treatment improves PTSD symptomatology in a rat model
Aga‐Mizrachi, S., Cymerblit‐Sabba, A., Gurman, O., Balan, A., Shwam, G., Deshe, R., Miller, L., Gorodetsky, N., Heinrich, N., Tzezana, O., et al. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.82 · Cited by 41
Norepinephrine transporter availability in brown fat is reduced in obesity: a human PET study with [11C] MRB
RANGEL, E. S., Gallezot, J., Yeckel, C. W., Lam, W., Belfort‐DeAguiar, R., Chen, M.-K., Carson, R. E., Sherwin, R., & Hwang, J. J. (2019) · International Journal of Obesity · doi:10.1038/s41366-019-0471-4 · Cited by 41
Self-citation
Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naïve children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study
Chou, T.-L., Chia, S., Shang, C.-Y., & Gau, S. S.-F. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.08.024 · Cited by 44
Association of norepinephrine transporter methylation with in vivo NET expression and hyperactivity–impulsivity symptoms in ADHD measured with PET
Sigurdardottir, H., Kranz, G., Rami-Mark, C., James, G. M., Vanicek, T., Gryglewski, G., Berroterán-Infante, N., Kautzky, A., Hienert, M., Traub-Weidinger, T., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0461-x · Cited by 34
An evaluation of the pharmacokinetics of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder
Frölich, J., Banaschewski, T., Döpfner, M., & Görtz‐Dorten, A. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.922542 · Cited by 40
Comparative Effects of Methylphenidate, Modafinil, and MDMA on Response Inhibition Neural Networks in Healthy Subjects
Schmidt, A., Müller, F., Dolder, P. C., Schmid, Y., Zanchi, D., Liechti, M. E., & Borgwardt, S. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx037 · Cited by 41
Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence
Simmler, L. D., Wandeler, R., & Liechti, M. E. (2013) · BMC Research Notes · doi:10.1186/1756-0500-6-220 · Cited by 38
Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets
Bruggisser, M., Bodmer, M., & Liechti, M. E. (2011) · Swiss Medical Weekly · doi:10.4414/smw.2011.13267 · Cited by 38
Antidepressant drug development: Focus on triple monoamine reuptake inhibition
Lane, R. M. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114553252 · Cited by 41
Baicalin regulates the dopamine system to control the core symptoms of ADHD
Zhou, R., Wang, J., Han, X., Ma, B., Yuan, H., & Song, Y. (2019) · Molecular Brain · doi:10.1186/s13041-019-0428-5 · Cited by 37
The effects of chronic administration of stimulant and non-stimulant medications on executive functions in ADHD: A systematic review and meta-analysis
Isfandnia, F., El Masri, S., Radua, J., & Rubia, K. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105703 · Cited by 36
Disrupted brain functional networks in drug‐naïve children with attention deficit hyperactivity disorder assessed using graph theory analysis
Chen, Y., Huang, X., Wu, M. C., Li, K., Hu, X., Jiang, P., Chen, L., He, N., Dai, J., Wang, S., et al. (2019) · Human Brain Mapping · doi:10.1002/hbm.24743 · Cited by 35
Methylphenidate Causes Behavioral Impairments and Neuron and Astrocyte Loss in the Hippocampus of Juvenile Rats
Schmitz, F., Pierozan, P., Rodrigues, A. F., Biasibetti, H., Grunevald, M., Pettenuzzo, L. F., Scaini, G., STRECK, E. L., Netto, C. A., & Wyse, Â. T. D. S. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9987-y · Cited by 38
Methylphenidate Decreases ATP Levels and Impairs Glutamate Uptake and Na+,K+-ATPase Activity in Juvenile Rat Hippocampus
Schmitz, F., Pierozan, P., Rodrigues, A. F., Biasibetti, H., Grings, M., Zanotto, B., Coelho, D. M., Vargas, C. R., Leipnitz, G., & Wyse, A. T. S. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0289-1 · Cited by 35
Abuse and dependence liability analysis of methylphenidate in the spontaneously hypertensive rat model of attention-deficit/hyperactivity disorder (ADHD): what have we learned?
Peña, I. D., & Cheong, J. H. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0037-2 · Cited by 35
Epilepsy and Attention Deficit Hyperactivity Disorder: Connection, Chance, and Challenges
Fan, H., Chiang, K.-L., Chang, K., Chen, C., & Tsai, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065270 · Cited by 39
Mapping α2Adrenoceptors of the Human Brain with11C-Yohimbine
Nahimi, A., Jakobsen, S., Munk, O. L., Vang, K., Phan, J.-A., Rodell, A. B., & GJEDDE, A. H. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.145565 · Cited by 34
PharmGKB summary
Stevens, T., Sangkuhl, K., Brown, J. T., Altman, R. B., & Klein, T. E. (2019) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000376 · Cited by 37
Methylphenidate Side Effect Profile Is Influenced by Genetic Variation in the Attention-Deficit/Hyperactivity Disorder-Associated CES1 Gene
Johnson, K. A., Barry, E., Lambert, D., Fitzgerald, M., McNicholas, F., Kirley, A., Gill, M., Bellgrove, M. A., & Hawi, Z. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2013.0032 · Cited by 34
Changes in Endogenous Dopamine Induced by Methylphenidate Predict Functional Connectivity in Nonhuman Primates
Birn, R. M., Converse, A. K., Rajala, A. Z., Alexander, A. L., Block, W. F., McMillan, A. B., Christian, B. T., Filla, C., Murali, D., Hurley, S. A., et al. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.2513-18.2018 · Cited by 34
Environmental Enrichment Preceding Early Adulthood Methylphenidate Treatment Leads to Long Term Increase of Corticosterone and Testosterone in the Rat
Avital, A., Dolev, T., Aga‐Mizrachi, S., & Zubedat, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022059 · Cited by 33
A mechanistic model of ADHD as resulting from dopamine phasic/tonic imbalance during reinforcement learning
Véronneau-Veilleux, F., Robaey, P., Ursino, M., & Nekka, F. (2022) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2022.849323 · Cited by 32
Ex Vivo and In Vivo Evaluation of the Norepinephrine Transporter Ligand [11C]MRB for Brown Adipose Tissue Imaging
Lin, S.-F., Fan, X., Yeckel, C. W., Weinzimmer, D. P., Mulnix, T., Gallezot, J., Carson, R. E., Sherwin, R. S., & Ding, Y. (2012) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2012.04.005 · Cited by 32
Self-citation
Recent Advances and Challenges of the Drugs Acting on Monoamine Transporters
Xue, W., Fu, T., Zheng, G., Tu, G., Zhang, Y., Yang, F., Tao, L., Yao, L., & Zhu, F. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181009123218 · Cited by 34
Methylphenidate and environmental enrichment ameliorate the deleterious effects of prenatal stress on attention functioning
Zubedat, S., Aga‐Mizrachi, S., Cymerblit‐Sabba, A., Ritter, A., Nachmani, M., & Avital, A. (2015) · Stress · doi:10.3109/10253890.2015.1023790 · Cited by 32
Contribution of Clinical Neuroimaging to the Understanding of the Pharmacology of Methylphenidate
Zimmer, L. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.04.001 · Cited by 32
Selective activation of Dopamine D3 receptors and norepinephrine transporter blockade enhances sustained attention
Marshall, C. A., Brodnik, Z. D., Mortensen, O. V., Reith, M. E. A., Shumsky, J. S., Waterhouse, B. D., España, R. A., & Kortagere, S. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.01.003 · Cited by 31
Imaging human brown adipose tissue under room temperature conditions with 11C-MRB, a selective norepinephrine transporter PET ligand
Hwang, J. J., Yeckel, C. W., Gallezot, J., Aguiar, R. B. D., Ersahin, D., Gao, H., Kapinos, M., Nabulsi, N., Huang, Y. H., Cheng, D., et al. (2015) · Metabolism · doi:10.1016/j.metabol.2015.03.001 · Cited by 31
Self-citation
Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults
Hopkins, S. C., Sunkaraneni, S., Skende, E., Hing, J. P., Passarell, J. A., Loebel, A. D., & Koblan, K. S. (2015) · Clinical Drug Investigation · doi:10.1007/s40261-015-0358-7 · Cited by 30
Neurobiology of Attention Deficit Hyperactivity Disorder
Faraone, S. V., & Radonjić, N. V. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_33-1 · Cited by 33
The “highs and lows” of the human brain on dopaminergics: Evidence from neuropharmacology
Martins, D., Mehta, M. A., & Prata, D. P. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.06.003 · Cited by 32
Methylphenidate Attenuates the Cognitive and Mood Alterations Observed inMbnl2Knockout Mice and Reduces Microglia Overexpression
Ramon‐Duaso, C., Gener, T., Consegal, M., Fernández-Avilés, C., Gallego, J., Castarlenas, L., Swanson, M. S., de la Torre, R., Maldonado, R. J., Puig, M. V., et al. (2018) · Cerebral Cortex · doi:10.1093/cercor/bhy164 · Cited by 32
Why maximum tolerated dose?
Stampfer, H. G., Gabb, G. M., & Dimmitt, S. B. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14032 · Cited by 28
Dissociations between cognitive and motor effects of psychostimulants and atomoxetine in hyperactive DAT-KO mice
Del’Guidice, T., Lemasson, M., Etiévant, A., Manta, S., Magno, L. A. V., Escoffier, G., Roman, F. S., & Beaulieu, J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3212-8 · Cited by 30
Clinical and neurobiological factors in the management of treatment refractory attention-deficit hyperactivity disorder
Shim, S.-H., Yoon, H.-J., Bak, J., Hahn, S., & Kim, Y. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.04.007 · Cited by 31
Differential Treatment Effects of Methylphenidate and Atomoxetine on Executive Functions in Children with Attention-Deficit/Hyperactivity Disorder
Wu, C., Shang, C., Lin, H., & Gau, S. S. (2021) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2020.0146 · Cited by 29
From neurons to brain networks, pharmacodynamics of stimulant medication for ADHD
Parlatini, V., Bellato, A., Murphy, D., & Cortese, S. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105841 · Cited by 26

Authors: Hannestad, J., Gallezot, J.-D., Planeta-Wilson, B., Lin, S.-F., Williams, W. A., van Dyck, C. H., Malison, R. T., Carson, R. E., & Ding, Y.-S.
Affiliations: Yale University (US)
Corresponding author: Ding, Yu-Shin
ORCID: Hannestad, Jonas
Gallezot, Jean-Dominique
van Dyck, Christopher H.
Malison, Robert T.
Carson, Richard E.
Ding, Yu-Shin
Venue: Biological Psychiatry
Publisher: Elsevier BV
Published: 2010-11
Volume: 68
Issue: 9
Pages: 854-860
ISSN: 0006-3223 (ISSN-L)
DOI: 10.1016/j.biopsych.2010.06.017
PMC: PMC3742016
OpenAlex: W2110412456
Cited by: 236
References: 41
Citations by year: 2026: 6 · 2025: 10 · 2024: 9 · 2023: 13 · 2022: 12 · 2021: 8 · 2020: 12 · 2019: 18 · 2018: 16 · 2017: 19 · 2016: 18 · 2015: 20 · 2014: 20 · 2013: 26 · 2012: 18
FWCI: 12.03
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Biological Psychiatry (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute on Drug Abuse (DA019062, R56DA19062)
National Center for Research Resources (UL1 RR024139)
National Institutes of Health, and National Institutes of Health roadmap for Medical Research (K12 DA000167)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords: methylphenidate, norepinephrine transporter, attention deficit hyperactivity disorder, dose-response relationship, thalamus, binding potential, dopamine transporter, mechanism of action
MeSH terms: Reboxetine, Adult, Central Nervous System Stimulants, Brain, Dose-Response Relationship, Drug, Female, Humans, Magnetic Resonance Imaging, Male, Methylphenidate, Morpholines, Radioligand Assay, Positron-Emission Tomography, Norepinephrine Plasma Membrane Transport Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clinically Relevant Doses of Methylphenidate Significantly Occupy Norepinephrine Transporters in Humans In Vivo

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks